{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:45:28Z","timestamp":1778564728738,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clinthera.2019.01.016","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T21:18:31Z","timestamp":1550783911000},"page":"625-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fatigue in Mastocytosis: A Case Series"],"prefix":"10.1016","volume":"41","author":[{"given":"Jens","family":"Vikse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roald","family":"Omdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.01.016_bib1","first-page":"620","article-title":"Mast cell: a multi-functional master cell","volume":"6","author":"Krystel-Whittemore","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2019.01.016_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/imr.12629","article-title":"Non-IgE mediated mast cell activation","volume":"282","author":"Redegeld","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2019.01.016_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.01.016_bib4","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.01.016_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.01.016_bib6","doi-asserted-by":"crossref","first-page":"e39468","DOI":"10.1371\/journal.pone.0039468","article-title":"Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression","volume":"7","author":"Moura","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2019.01.016_bib7","doi-asserted-by":"crossref","first-page":"e1197","DOI":"10.1038\/tp.2017.137","article-title":"Neuroimaging evidence of brain abnormalities in mastocytosis","volume":"7","author":"Boddaert","year":"2017","journal-title":"Transl Psychiatr"},{"key":"10.1016\/j.clinthera.2019.01.016_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2016.03.013","article-title":"Mastocytosis in adulthood and neuropsychiatric disorders","volume":"174","author":"Georgin-Lavialle","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.clinthera.2019.01.016_bib9","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/mp.2015.216","article-title":"Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis","volume":"21","author":"Georgin-Lavialle","year":"2016","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.clinthera.2019.01.016_bib10","first-page":"449","article-title":"New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators","volume":"32","author":"Caraffa","year":"2018","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2019.01.016_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/1073858416687249","article-title":"Neuroinflammation, mast cells, and glia: dangerous liaisons","volume":"23","author":"Skaper","year":"2017","journal-title":"Neuroscientist"},{"key":"10.1016\/j.clinthera.2019.01.016_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3389\/fnins.2015.00225","article-title":"Brain \u201cfog,\u201d inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin","volume":"9","author":"Theoharides","year":"2015","journal-title":"Front Neurosci"},{"key":"10.1016\/j.clinthera.2019.01.016_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00019052-199612000-00011","article-title":"Mechanisms and management of fatigue in progressive neurological disorders","volume":"9","author":"Krupp","year":"1996","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clinthera.2019.01.016_bib14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/rheumatology\/keq454","article-title":"Biological mechanisms of chronic fatigue","volume":"50","author":"Norheim","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2019.01.016_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tins.2013.10.003","article-title":"The neuroimmune basis of fatigue","volume":"37","author":"Dantzer","year":"2014","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.clinthera.2019.01.016_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0149-7634(88)80004-6","article-title":"Biological basis of the behavior of sick animals","volume":"12","author":"Hart","year":"1988","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.clinthera.2019.01.016_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2058738418803252","article-title":"Fatigue is common and severe in patients with mastocytosis","volume":"32","author":"Omdal","year":"2018","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2019.01.016_bib18","first-page":"1896","article-title":"Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients","volume":"31","author":"Wolfe","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.clinthera.2019.01.016_bib19","first-page":"4447","article-title":"Role of interleukin-1 beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice","volume":"12","author":"Bluth\u00e9","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.clinthera.2019.01.016_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1749-6632.1997.tb48395.x","article-title":"Central interleukin-1 receptors as mediators of sickness","volume":"823","author":"Kelley","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2019.01.016_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-004-0463-z","article-title":"The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis\u2014a pilot study","volume":"25","author":"Omdal","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2019.01.016_bib22","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.2337\/dc11-1196","article-title":"Inhibition of IL-1\u03b2 improves fatigue in type 2 diabetes","volume":"34","author":"Cavelti-Weder","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2019.01.016_bib23","first-page":"499","article-title":"Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism","volume":"317","author":"Bluth\u00e9","year":"1994","journal-title":"Comptes Rendus de L'Academie des Sci"},{"key":"10.1016\/j.clinthera.2019.01.016_bib24","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.1073\/pnas.1205207109","article-title":"Interleukin-1R3 mediates interleukin-1-induced potassium current increase through fast activation of Akt kinase","volume":"109","author":"Qian","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2019.01.016_bib25","doi-asserted-by":"crossref","first-page":"18048","DOI":"10.1523\/JNEUROSCI.4067-11.2011","article-title":"Neuron-specific effects of interleukin-1\u03b2 are mediated by a novel isoform of the IL-1 receptor accessory protein","volume":"31","author":"Huang","year":"2011","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.clinthera.2019.01.016_bib26","first-page":"8439594","article-title":"Effects of a moderately lower temperature on the proliferation and degranulation of rat mast cells","volume":"2016","author":"Wang","year":"2016","journal-title":"J\u00a0Immunol Res"},{"issue":"1","key":"10.1016\/j.clinthera.2019.01.016_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13601-015-0076-5","article-title":"The role of IL-33 and mast cells in allergy and inflammation","volume":"5","author":"Saluja","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.clinthera.2019.01.016_bib28","first-page":"1061","article-title":"IL-33 mediates allergy through mast cell activation: potential inhibitory effect of certain cytokines","volume":"32","author":"Tettamanti","year":"2018","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2019.01.016_bib29","first-page":"1355","article-title":"Stimulated mast cells release inflammatory cytokines: potential suppression and therapeutical aspects","volume":"32","author":"Varvara","year":"2018","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2019.01.016_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2012.00082","article-title":"Mast cells respond to cell injury through the recognition of IL-33","volume":"3","author":"Lunderius-Andersson","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2019.01.016_bib31","article-title":"Interleukin-1 family cytokines and mast cells: activation and inhibition","volume":"33","author":"Gallenga","year":"2019","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2019.01.016_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0889-1591(90)90008-E","article-title":"Nerve growth factor released into the bloodstream following intraspecific fighting induces mast cell degranulation in adult male mice","volume":"4","author":"De Simone","year":"1990","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.clinthera.2019.01.016_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2567.2007.02705.x","article-title":"Neuropeptides activate human mast cell degranulation and chemokine production","volume":"123","author":"Kulka","year":"2008","journal-title":"Immunology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:48Z","timestamp":1758962988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819300542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0149291819300542"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.01.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatigue in Mastocytosis: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}